Cart
sales@molnova.com
(Tyr6,D-Phe7,D-His9)-Substance P (6-11)
CAS No. 145194-26-9
(Tyr6,D-Phe7,D-His9)-Substance P (6-11)( ——— )
Catalog No. M40456 CAS No. 145194-26-9
[Tyr6,D-Phe7,D-His9]-Substance P (6-11) is a tachykinin NK1 receptor antagonist that antagonizes Histamine induced hyperalgesia.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | Get Quote | Get Quote |
|
| 50MG | Get Quote | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
Biological Information
-
Product Name(Tyr6,D-Phe7,D-His9)-Substance P (6-11)
-
NoteResearch use only, not for human use.
-
Brief Description[Tyr6,D-Phe7,D-His9]-Substance P (6-11) is a tachykinin NK1 receptor antagonist that antagonizes Histamine induced hyperalgesia.
-
Description[Tyr6,D-Phe7,D-His9]-Substance P (6-11) is a tachykinin NK1 receptor antagonist that antagonizes Histamine induced hyperalgesia.
-
In Vitro———
-
In Vivo———
-
Synonyms———
-
PathwayOthers
-
TargetOther Targets
-
Recptor———
-
Research Area———
-
Indication———
Chemical Information
-
CAS Number145194-26-9
-
Formula Weight856.07
-
Molecular FormulaC44H57N9O7S
-
Purity>98% (HPLC)
-
Solubility———
-
SMILES———
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Sakurada, et al. "Possible involvement of tachykinin NK1 and NMDA receptors in histamine-induced hyperalgesia in mice." European journal of pharmacology 434.1-2 (2002): 29-34.?
molnova catalog
related products
-
Dimethyl itaconate
Dimethyl Itaconate is a chemical reagent used in the synthesis of functionalized 2-isoxazolines used in fragment-based drug discovery.
-
Eprodisate disodium
Eprodisate Disodium is the orally available disodium salt form of Eprodisate, a negatively charged sulfonated inhibitor of fibrillogenesis, that can be used in the treatment of amyloid A (AA) amyloidosis.
-
BRCA1-IN-2
BRCA1-IN-2 is a cell membrane-crossing BRCA1 protein-protein interaction (PPI) inhibitor with antitumor activity that acts by disrupting the interaction of BRCA1 (BRCT)2 with proteins.
